Literature DB >> 25215150

Flashback phenomenon and residual neurological deficits after the use of "bath salt" 3, 4- methylenedioxypyrovalerone.

Aaron R Mangold1, Thomas P Bravo2, Stephen J Traub3, Steven A Maher3, Christopher A Lipinski4.   

Abstract

BACKGROUND: The use and abuse of designer drugs has been recognized for decades; however there are many derivatives of compounds that make their way into the community. Abuse of compound(s) known on the street as "bath salt" is on the rise.
METHODS: We report the case of a 33-year-old man who complained of "flashbacks" and right arm shaking that followed a night of "bath salt" snorting. The active compound methylenedioxypyrovalerone methamphetamine (MDPV) was confirmed; however, analysis of three different "bath salt" products showed difference in their active components.
RESULTS: The patient's symptoms remained stable and he was discharged home after observation in the emergency department with instructions to return for any symptom progression.
CONCLUSION: Practitioners should be aware of the abuse of the compounds and that not all "bath salt" products contain MDPV.

Entities:  

Keywords:  Emergency Department; Methylenedioxypyrovalerone methamphetamine; Residual neurological deficits

Year:  2014        PMID: 25215150      PMCID: PMC4129860          DOI: 10.5847/wjem.j.issn.1920-8642.2014.01.011

Source DB:  PubMed          Journal:  World J Emerg Med        ISSN: 1920-8642


  16 in total

1.  Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States.

Authors:  Henry A Spiller; Mark L Ryan; Robert G Weston; Joanne Jansen
Journal:  Clin Toxicol (Phila)       Date:  2011-07       Impact factor: 4.467

2.  Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.

Authors:  A P Monte; S R Waldman; D Marona-Lewicka; D B Wainscott; D L Nelson; E Sanders-Bush; D E Nichols
Journal:  J Med Chem       Date:  1997-09-12       Impact factor: 7.446

Review 3.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.

Authors:  D E Nichols
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

4.  The use of labetalol in the management of cocaine crisis.

Authors:  G R Gay; K A Loper
Journal:  Ann Emerg Med       Date:  1988-03       Impact factor: 5.721

Review 5.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

6.  Emergency department visits after use of a drug sold as "bath salts"--Michigan, November 13, 2010-March 31, 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-05-20       Impact factor: 17.586

7.  Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use.

Authors:  Michael H Hoskins; Rebecca M Leleiko; Julie J Ramos; Srikanth Sola; Patrick M Caneer; Bobby V Khan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2010-03       Impact factor: 2.457

Review 8.  Multiple molecular and neuropharmacological effects of MDMA (Ecstasy).

Authors:  Rabi Simantov
Journal:  Life Sci       Date:  2004-01-02       Impact factor: 5.037

Review 9.  'Designer drugs'. A problem in clinical toxicology.

Authors:  J F Buchanan; C R Brown
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jan-Dec

10.  Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors.

Authors:  J F Nash; B L Roth; J D Brodkin; D E Nichols; G A Gudelsky
Journal:  Neurosci Lett       Date:  1994-08-15       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.